Histopathological Growth Patterns and Survival After Resection of Colorectal Liver Metastasis: An External Validation Study.


Journal

JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827

Informations de publication

Date de publication:
06 2021
Historique:
received: 16 11 2020
revised: 18 01 2021
accepted: 18 03 2021
entrez: 31 5 2021
pubmed: 1 6 2021
medline: 1 6 2021
Statut: epublish

Résumé

After resection of colorectal cancer liver metastases (CRLM), 2 main histopathological growth patterns can be observed: a desmoplastic and a nondesmoplastic subtype. The desmoplastic subtype has been associated with superior survival. These findings require external validation. An international multicenter retrospective cohort study was conducted in patients treated surgically for CRLM at 3 tertiary hospitals in the United States and the Netherlands. Determination of histopathological growth patterns was performed on hematoxylin and eosin-stained sections of resected CRLM according to international guidelines. Patients displaying a desmoplastic histopathological phenotype (only desmoplastic growth observed) were compared with patients with a nondesmoplastic phenotype (any nondesmoplastic growth observed). Cutoff analyses on the extent of nondesmoplastic growth were performed. Overall survival (OS) and disease-free survival (DFS) were estimated using Kaplan-Meier and multivariable Cox analysis. All statistical tests were 2-sided. In total 780 patients were eligible. A desmoplastic phenotype was observed in 19.1% and was associated with microsatellite instability (14.6% vs 3.6%, This external validation study confirms the remarkably good prognosis after surgery for CRLM in patients with a desmoplastic phenotype. The extent of nondesmoplastic growth does not affect prognosis.

Sections du résumé

Background
After resection of colorectal cancer liver metastases (CRLM), 2 main histopathological growth patterns can be observed: a desmoplastic and a nondesmoplastic subtype. The desmoplastic subtype has been associated with superior survival. These findings require external validation.
Methods
An international multicenter retrospective cohort study was conducted in patients treated surgically for CRLM at 3 tertiary hospitals in the United States and the Netherlands. Determination of histopathological growth patterns was performed on hematoxylin and eosin-stained sections of resected CRLM according to international guidelines. Patients displaying a desmoplastic histopathological phenotype (only desmoplastic growth observed) were compared with patients with a nondesmoplastic phenotype (any nondesmoplastic growth observed). Cutoff analyses on the extent of nondesmoplastic growth were performed. Overall survival (OS) and disease-free survival (DFS) were estimated using Kaplan-Meier and multivariable Cox analysis. All statistical tests were 2-sided.
Results
In total 780 patients were eligible. A desmoplastic phenotype was observed in 19.1% and was associated with microsatellite instability (14.6% vs 3.6%,
Conclusions
This external validation study confirms the remarkably good prognosis after surgery for CRLM in patients with a desmoplastic phenotype. The extent of nondesmoplastic growth does not affect prognosis.

Identifiants

pubmed: 34056541
doi: 10.1093/jncics/pkab026
pii: pkab026
pmc: PMC8152695
doi:

Substances chimiques

Antineoplastic Agents 0
KRAS protein, human 0
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Multicenter Study Validation Study

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press.

Références

Ann Surg Oncol. 2019 Dec;26(13):4599-4607
pubmed: 31641947
Clin Exp Metastasis. 2019 Apr;36(2):109-118
pubmed: 30843120
HPB (Oxford). 2020 Mar;22(3):351-357
pubmed: 31668753
HPB (Oxford). 2020 Jun;22(6):911-919
pubmed: 31735649
Br J Surg. 2014 Dec;101(13):1681-91
pubmed: 25331841
Mod Pathol. 2014 Dec;27(12):1641-8
pubmed: 24851832
Cancer. 2014 Aug 1;120(15):2316-24
pubmed: 24737664
BMJ Open Gastroenterol. 2018 Jul 27;5(1):e000217
pubmed: 30073092
Am J Surg. 2014 Apr;207(4):493-8
pubmed: 24112674
Ann Surg. 2006 Aug;244(2):254-9
pubmed: 16858188
J Oncol. 2012;2012:907971
pubmed: 22919385
Clin Cancer Res. 2013 Aug 1;19(15):4104-13
pubmed: 23741067
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Br J Cancer. 2017 Nov 7;117(10):1427-1441
pubmed: 28982110
Ann Surg Oncol. 2019 Dec;26(13):4587-4598
pubmed: 31605342
Br J Cancer. 2005 May 9;92(9):1746-53
pubmed: 15856045
Clin Cancer Res. 2019 Oct 1;25(19):5843-5851
pubmed: 31221662
J Natl Cancer Inst. 2018 Aug 1;110(8):803-811
pubmed: 29873743
BMC Cancer. 2019 Apr 5;19(1):327
pubmed: 30953467
Clin Epidemiol. 2012;4:283-301
pubmed: 23152705
Br J Cancer. 2020 Jul;123(2):196-206
pubmed: 32418992
Nihon Geka Hokan. 1991 May 1;60(3):154-64
pubmed: 1776910
Clin Exp Metastasis. 2020 Oct;37(5):593-605
pubmed: 32691187
Eur J Surg Oncol. 2020 Sep;46(9):1742-1755
pubmed: 32303416
Nat Med. 2016 Nov;22(11):1294-1302
pubmed: 27748747
Clin Exp Metastasis. 2012 Aug;29(6):541-9
pubmed: 22476470
Gastroenterology. 2010 Jun;138(6):2073-2087.e3
pubmed: 20420947
J Natl Cancer Inst. 2014 Jun 12;106(7):
pubmed: 24925349
Clin Exp Metastasis. 2019 Aug;36(4):311-319
pubmed: 31134394
Semin Cancer Biol. 2018 Oct;52(Pt 2):86-93
pubmed: 29355613
J Clin Oncol. 2017 Jun 10;35(17):1938-1944
pubmed: 28426374
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
J Pathol. 2001 Oct;195(3):336-42
pubmed: 11673831
Front Oncol. 2020 Mar 05;10:249
pubmed: 32195184
Clin Exp Metastasis. 2015 Apr;32(4):369-81
pubmed: 25822899
Angiogenesis. 2019 May;22(2):355-368
pubmed: 30637550
JAMA Surg. 2018 Jul 18;153(7):e180996
pubmed: 29799910

Auteurs

Diederik J Höppener (DJ)

Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Boris Galjart (B)

Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Pieter M H Nierop (PMH)

Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Florian E Buisman (FE)

Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Eric P van der Stok (EP)

Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Robert R J Coebergh van den Braak (RRJ)

Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Martin J van Amerongen (MJ)

Department of Radiology, Radboud University Medical Center, Nijmegen, the Netherlands.

Vinod P Balachandran (VP)

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

William R Jarnagin (WR)

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

T Peter Kingham (TP)

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Michail Doukas (M)

Department of Pathology, Erasmus MC, Rotterdam, the Netherlands.

Jinru Shia (J)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Iris D Nagtegaal (ID)

Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.

Peter B Vermeulen (PB)

Translational Cancer Research Unit (GZA Hospitals and University of Antwerp), Antwerp, Belgium.

Bas Groot Koerkamp (BG)

Department of Surgery, Erasmus MC, Rotterdam, the Netherlands.

Dirk J Grünhagen (DJ)

Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Johannes H W de Wilt (JHW)

Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.

Michael I D'Angelica (MI)

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Cornelis Verhoef (C)

Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH